• Wade Brown

    Wade Brown is the Head of Strategy and Research Operations in Cambridge for Bristol Myers Squibb (BMS), a role he has held since January 2021. He is responsible for Research and Early Development Operations at both the Kendall Square and Alewife sites as well as leading the strategic efforts for the Mechanisms of Cancer Resistance (MoCR) thematic research center in Cambridge. 

    Prior to his current role at BMS, Wade spent 17 years at Novartis in various scientific, operational and strategic roles across several divisions including Pharmaceuticals, Vaccines and Diagnostics and the Novartis Institutes for BioMedical Research (NIBR). In 2020, Wade led the COVID-19 crisis response team for NIBR. He also recently served as the Global Head of External Research Collaborations, Academic Partnerships & External Innovation. Here, Wade led a global team responsible for providing business guidance and transactional support to enable external scientific partnerships across Novartis’s research organization.

    Wade and his wife, Megan, are residents of Needham, MA where they live with their three children. He remains actively involved at his alma mater, Boston College, and is a member of the Board of Trustees at St. Columbkille Partnership School in Brighton, MA.

    Learn More
  • Kristin Goppel

    Kristin is a Consultant on the Program Management team at Avania Clinical, a global CRO focused on advancing medical devices, novel technology and combination products from feasibility through post-approval trials. Her team provides early stage strategic consulting services that include feasibility and benchmarking analysis, pre-clinical study design, and tailored regulatory strategies. Prior, as the Senior Program Development Manager for Life Science Strategic Initiatives at Worcester Polytechnic Institute, she led demand-driven program development in biotechnology, medicinal chemistry, biomedical and chemical engineering, and project management for technical symposia, research partnerships and consulting contracts with industry and government partners.

    Kristin earned her B.S. in Chemical Engineering cum laude from Cornell University. After beginning her career in product design and development at Procter & Gamble and Arthur D. Little Inc., she then focused on her biotechnology interests with roles in process and project design engineering at Anika Therapeutics and Genzyme Corporation. She first partnered with the MassBioEd team during her tenure as WPI’s Associate Director of Pre-collegiate Outreach, and continues to support the valuable work the foundation does as a member of the Board and several program steering committees.

    Learn More
  • Michael Levy

    Michael has served on the Board of Directors and as Treasurer of MassBioEd since June 2019. Separately, he is the Senior Director of Accounting at Relay Therapeutics, a clinical stage precision medicines company focused on protein motion, which is used to facilitate the selection and advancement of unique product candidates into novel therapies. Before joining Relay Therapeutics, he worked as the Corporate Controller at Triplet Therapeutics and as an Assurance Senior Manager in Ernst & Young LLP’s Life Sciences Practice in Cambridge, MA  for over 11 years. In connection therewith, he assisted clients in the life sciences industry with various accounting and auditing matters. Finally, he received his Bachelor of Science in Business Administration from Boston University and is a member of the American Institute of Certified Public Accountants, as well as the Massachusetts Society of Certified Public Accountants.

    Learn More
  • Stacie Sawchak Aarestad

    Stacie is a partner in Foley Hoag’s Securities Practice Group and M&A Practice Group. She focuses her practice on corporate and securities law matters, public company representation and merger and acquisition transactions. She represents issuers in a broad range of capital market transactions, including public and private offerings of debt and equity securities and also advises companies with respect to tender offers, exchange offers, debt repurchases and stock buybacks. Stacie received her B.A. magna cum laude from Colgate University in 1991 and her J.D. magna cum laude from Boston University School of Law in 1997.

    Learn More
  • Lauren Celano

    Lauren is the co-founder and CEO of Propel Careers, a life science search and career development firm focused on connecting talented individuals with entrepreneurial life sciences companies.  Propel works with current leaders and actively cultivates future leaders through full time placement, internships, mentoring, career coaching, and networking.  Propel Careers is engaged  across all areas of life sciences, including therapeutics, medical devices, healthcare IT, diagnostics, consulting, venture capital, and investment banking. Prior to Propel Careers, Lauren was a senior account manager for SNBL USA where she worked with emerging biotech companies in Europe, Asia, and the US to help characterize and advance their drug molecules. Prior to SNBL USA, she held business development positions with Aptuit and Quintiles, where she focused on IND enabling studies to advance therapeutics from discovery into the clinic.  Earlier in her career, Lauren held positions as a marketing manager and account manager at Absorption Systems, where she was responsible for managing life sciences companies in the northeastern United States.  She has a B.S. in Biochemistry and Molecular Biology from Gettysburg College and an MBA with a focus in the health sector and entrepreneurship from Boston University. Lauren is the Vice-Chair on the Board of MassBioEd and the Advisory Boards of the Boston University School of Public Health Pharmaceuticals Program, the Professional Science Masters Program at Framingham State University and NE GWISE. She also serves on the selection committee for the Life Sciences Immigrant Entrepreneur of the Year Award since 2014 with the Immigrant Learning Center.

    Learn More
  • Christopher Murphy

    Christopher has been a board member at MassBioEd since 2014 and is the Chief Executive Officer at Akron Bio. Prior, he was Vice President and General Manager of Viral Vector Services in Thermo Fisher Scientific’s Pharma Services Group.  He transitioned into this role when Thermo Fisher acquired Brammer Bio, where he served as chief operating officer. Christopher has more than 30 years of experience in biopharmaceutical manufacturing, process development, plant operations, and quality system implementation.  Prior to joining Brammer Bio, he served as general manager for the Sanofi-Genzyme Allston Landing site overseeing operations and leading an integrated remediation program associated with the consent decree. Christopher has led gene therapy operations and recombinant protein manufacturing at Genzyme and Bioreliance and he began his career in viral vaccine development at American Cyanamid/Wyeth (now Pfizer) in Pearl River, NY. He has a M.S. in biochemistry at New York Medical College, and his B.S. in biology at Rutgers University.

    Learn More